Order Article Reprints

Novak D, Janota B, Hörmann AA, Sawicka A, Kroselj M, Hubalewska-Dydejczyk A, Fani M, Mikolajczak R, Kolenc P, Decristoforo C, et al. Development of the ^99mTc-Labelled SST₂ Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics. 2023; 15(3):885. https://doi.org/10.3390/pharmaceutics15030885

Novak, Doroteja, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, and et al. 2023. "Development of the ^99mTc-Labelled SST₂ Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study" Pharmaceutics 15, no. 3: 885. https://doi.org/10.3390/pharmaceutics15030885

Novak, D., Janota, B., Hörmann, A. A., Sawicka, A., Kroselj, M., Hubalewska-Dydejczyk, A., Fani, M., Mikolajczak, R., Kolenc, P., Decristoforo, C., & Garnuszek, P. (2023). Development of the ^99mTc-Labelled SST₂ Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics, 15(3), 885. https://doi.org/10.3390/pharmaceutics15030885